ExCellThera announces FDA and Health Canada clearance for new clinical trials

ExCellThera

Congratulations to our client, ExCellThera Inc., a clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use. ExCellThera announced on March 25, 2019 that its lead technology, ECT-001, will be used as part of two new clinical trials in patients with high-risk leukemia. The announcement follows the recent clearance of the company’s Investigational New Drug (IND) application by the U.S. Food and  Drug Administration (FDA) and of a clinical trial application by Health Canada, in each case for the use of ECT-001 to treat patients with high-risk leukemia and myelodysplasia.

READ FULL NEWS RELEASE

Join over 6000 medical device professionals who receive our engineering, regulatory and commercialization insights and tips every month.